Teachers Retirement System of The State of Kentucky Has $85.62 Million Position in Gilead Sciences, Inc. $GILD

Teachers Retirement System of The State of Kentucky cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.0% during the 1st quarter, Holdings Channel reports. The fund owned 614,360 shares of the biopharmaceutical company’s stock after selling 12,727 shares during the period. Gilead Sciences comprises approximately 0.7% of Teachers Retirement System of The State of Kentucky’s investment portfolio, making the stock its 13th largest position. Teachers Retirement System of The State of Kentucky’s holdings in Gilead Sciences were worth $85,623,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in shares of Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. State Street Corp grew its stake in shares of Gilead Sciences by 1.9% in the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock valued at $7,393,921,000 after buying an additional 1,151,213 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Gilead Sciences by 4.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock valued at $3,399,734,000 after buying an additional 1,195,269 shares during the period. Bank of America Corp DE increased its position in Gilead Sciences by 15.2% in the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after buying an additional 3,046,688 shares in the last quarter. Finally, Norges Bank bought a new stake in Gilead Sciences in the 4th quarter valued at about $2,617,152,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares in the company, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the sale, the chief executive officer directly owned 617,567 shares in the company, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 83,000 shares of company stock worth $10,824,500. 0.30% of the stock is owned by company insiders.

Gilead Sciences Stock Performance

Shares of GILD opened at $129.83 on Monday. The stock has a 50 day moving average of $129.78 and a 200 day moving average of $135.03. The company has a market capitalization of $161.19 billion, a price-to-earnings ratio of 17.69 and a beta of 0.32. Gilead Sciences, Inc. has a 12 month low of $107.75 and a 12 month high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the prior year, the company earned $1.81 EPS. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were given a dividend of $0.82 per share. The ex-dividend date was Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Citigroup increased their price target on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Rothschild & Co Redburn decreased their price objective on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Sunday. Truist Financial cut their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Finally, Leerink Partners reduced their price target on shares of Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Twenty-six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $159.04.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.